Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight

Handbook of Experimental Pharmacology

Volumn 209, Issue , 2012, Pages 357-381

  Engeli, Stefan ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Anandamide; Cachexia; Cannabinoid receptor; Endocannabinoids; Food intake; Obesity; Rimonabant; Taranabant; Tetrahydrocannabinol

Indexed keywords

AGENTS AFFECTING METABOLISM; AM 6545; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CAPSAICIN; CHOLECYSTOKININ; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; DRONABINOL; ENDOCANNABINOID; GHRELIN; LEPTIN; MELANOCORTIN; NABILONE; NEUROPEPTIDE; OREXIN; PLACEBO; RIMONABANT; SIBUTRAMINE; TARANABANT; UNCLASSIFIED DRUG; URB 447; ANOREXIGENIC AGENT;

ARTICLE; BIOAVAILABILITY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY METABOLISM; FOOD INTAKE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; HUNGER; LOW DRUG DOSE; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WEIGHT CONTROL; WEIGHT REDUCTION; ANIMAL; BRAIN; DRUG ANTAGONISM; DRUG EFFECT; EATING; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME;

ANIMALS; APPETITE DEPRESSANTS; APPETITE REGULATION; BRAIN; EATING; ENDOCANNABINOIDS; HUMANS; OBESITY; RECEPTORS, CANNABINOID; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84856348064     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-24716-3_17     Document Type: Article

References (114)

1. Abel EL1975) Cannabis: effects on hunger and thirst. Behav Biol 15:255-281
2. Abood ME2005) Molecular biology of cannabinoid receptors. Handb Exp Pharmacol 168:81-115
3. Addy C, Wright H, van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria- Bohorquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN III, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depre M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB2008) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78
4. Ameloot K, Janssen P, Scarpellini E, Vos R, Boesmans W, Depoortere I, Vanden BP, Tack J2010) Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther 31:1123-1131
5. Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, Le Fur G1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoidCB1) receptors. PsychopharmacologyBerl) 132:104-106 (Pubitemid 27303746)
6. Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG, Shapiro D, Heymsfield SB, Kaufman KD, Amatruda JM2010) A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J ObesLond) 34:919-935
7. Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, Morales JO, Murphy R, Powderly W, Plasse TF, Mosdell KW, Shepard KV1997) Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage 14:7-14 (Pubitemid 27287406)
8. Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD, Vosburg SK, Haney M2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. PsychopharmacologyBerl) 212:675-686
9. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrie P2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914 (Pubitemid 36368998)
10. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J, StumvollM(2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:3053-3060 (Pubitemid 44923642)
11. Burdyga G, Lal S, Varro A, Dimaline R, Thompson DG, Dockray GJ2004) Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 24:2708-2715 (Pubitemid 38380947)
12. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ2006) Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol 290:G1289-G1297 (Pubitemid 43788312)
13. Burdyga G, Varro A, Dimaline R, Thompson DG, Dockray GJ2010) Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype. Am J Physiol Gastrointest Liver Physiol 299:G63-G69
14. Burns HD, van Laere K, Sanabria-Bohorquez S, Hamill TG, Bormans G, Eng WS, Gibson R, Ryan C, Connolly B, Patel S, Krause S, Vanko A, van Hecken A, Dupont P, De Lepeleire I, Rothenberg P, Stoch SA, Cote J, Hagmann WK, Jewell JP, Lin LS, Liu P, Goulet MT, Gottesdiener K, Wagner JA, de Hoon J, Mortelmans L, Fong TM, Hargreaves RJ2007) [18F]MK-9470, a positron emission tomographyPET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 104:9800-9805 (Pubitemid 47175347)
15. Cani PD, Montoya ML, Neyrinck AM, Delzenne NM, Lambert DM2004) Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716Arimonabant) and oleoylethanolamide. Br J Nutr 92:757-761 (Pubitemid 39562153)
16. Carai MA, Colombo G, Maccioni P, Gessa GL2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data. CNS Drug Rev 12:91-99 (Pubitemid 44300378)
17. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA2007) Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 267:63-69
18. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL1998) Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63:L113-L117
19. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431 (Pubitemid 38063771)
20. Coté M, Matias I, Lemieux I, Petrosino S, Almeras N, Després JP, Di Marzo V2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J ObesLond) 31:692-699 (Pubitemid 46482358)
21. Després JP, Golay A, Sjostrom L2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134 (Pubitemid 41653104)
22. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613 (Pubitemid 19007296)
23. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949 (Pubitemid 23026736)
24. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825 (Pubitemid 32303781)
25. Di Marzo V, De Petrocellis L, Bisogno T2005) The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 168:147-185
26. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, Romano B, Orlando P, Capasso F, Izzo AA2008) The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153:1272-1280 (Pubitemid 351415503)
27. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, Piscitelli F, Westerbacka J, Soro-Paavonen A, Matias I, Van GL, Taskinen MR2009a) Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 161:715-722
28. Di Marzo V, Coté M, Matias I, Lemieux I, Arsenault BJ, Cartier A, Piscitelli F, Petrosino S, Almeras N, Després JP2009b) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52:213-217
29. Dipatrizio NV, Simansky KJ2008) Inhibiting parabrachial fatty acid amide hydrolase activity selectively increases the intake of palatable food via cannabinoid CB1 receptors. Am J Physiol Regul Integr Comp Physiol 295:R1409-R1414
30. Engeli S2008a) Dysregulation of the endocannabinoid system in obesity. J Neuroendocrinol 20Suppl 1):110-115 (Pubitemid 351559284)
31. Engeli S2008b) Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade. Obes Facts 1:8-15
32. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843 (Pubitemid 41401077)
33. Foltin RW, Fischman MW, Byrne MF1988) Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1-14
34. Fong TM, Heymsfield SB2009) Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions. Int J ObesLond) 33:947-955
35. Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP2007) Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-[[5-(t rifluoromethyl)pyridin- 2-yl]oxy]propanamideMK- 0364), in rodents. J Pharmacol Exp Ther 321:1013-1022 (Pubitemid 46762708)
36. Gagnon MA, Elie R1975) Effects of marijuana and D-amphetamine on the appetite, food consumption and various cardio-respiratory variables in man. Union Med Can 104:914-921
37. Gaoni Y, Mechoulam R1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646
38. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrie P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46:122-129 (Pubitemid 47171928)
39. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez dF2002) A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617 (Pubitemid 35356203)
40. Gorter R, Seefried M, Volberding P1992) Dronabinol effects on weight in patients with HIV infection. AIDS 6:127
41. Greenberg I, Kuehnle J, Mendelson JH, Bernstein JG1976) Effects of marihuana use on body weight and caloric intake in humans. PsychopharmacologyBerl) 49:79-84
42. Harrold JA, Elliott JC, King PJ, Widdowson PS, Williams G2002) Down-regulation of cannabinoid- 1CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 952:232-238
43. Hollister LE1971) Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 12:44-49
44. Howlett AC2005) Cannabinoid receptor signaling. Handb Exp Pharmacol 168:53-79
45. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202 (Pubitemid 34575709)
46. Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, Petrosino S, Di Marzo V2009) Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. Br J Pharmacol 158:451-461
47. Jamshidi N, Taylor DA2001) Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol 134:1151-1154 (Pubitemid 33097243)
48. Jbilo O, Ravinet Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P2005) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569 (Pubitemid 41279033)
49. Jo YH, Chen YJ, Chua SC Jr, Talmage DA, Role LW2005) Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 48:1055-1066 (Pubitemid 41814707)
50. Jones D2008) End of the line for cannabinoid receptor 1 as an anti-obesity target? Nat Rev Drug Discov 7:961-962
51. Jordan J, Schlaich M, Redon J, Narkiewicz K, Luft FC, Grassi G, Dixon J, Lambert G, Engeli S2011) European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. J Hypertens 29:189-193
52. Kipnes MS, Hollander P, Fujioka K, Gantz I, Seck T, Erondu N, Shentu Y, Lu K, Suryawanshi S, Chou M, Johnson-Levonas AO, Heymsfield SB, Shapiro D, Kaufman KD, Amatruda JM2010) A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes. Diabetes Obes Metab 12:517-531
53. Kirkham TC, Williams CM2001) Endogenous cannabinoids and appetite. Nutr Res Rev 14:65-86 (Pubitemid 32574404)
54. Kirkham TC, Williams CM, Fezza F, Di Marzo V2002) Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557 (Pubitemid 34717699)
55. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, Korbonits M2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201 (Pubitemid 40934612)
56. Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W2008) Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats. Int J ObesLond) 32:863-870 (Pubitemid 351670628)
57. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, BohmeGA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401-404
58. Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK2006) Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-trifluoromethyl)pyridin-2-yl]oxy} propanamideMK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584-7587 (Pubitemid 46033647)
59. Liu YL, Connoley IP, Wilson CA, Stock MJ2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/ Lep(ob) mice. Int J ObesLond) 29:183-187 (Pubitemid 40188413)
60. LoVerme J, Duranti A, Tontini A, Spadoni G, MorM, Rivara S, Stella N, Xu C, Tarzia G, Piomelli D2009) Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain inmice. BioorgMed ChemLett 19:639-643
61. Maccarrone M, Fride E, Bisogno T, Bari M, Cascio MG, Battista N, Finazzi AA, Suris R, Mechoulam R, Di Marzo V2005) Up-regulation of the endocannabinoid system in the uterus of leptin knockoutob/ob) mice and implications for fertility. Mol Hum Reprod 11:21-28 (Pubitemid 40330999)
62. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418:530-534 (Pubitemid 34851398)
63. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R,MajM, Pagotto U,Monteleone P, Di Marzo V2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-3180 (Pubitemid 44271774)
64. Matias I, Vergoni AV, Petrosino S, Ottani A, Pocai A, Bertolini A, Di Marzo V2008) Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology 54:206-212 (Pubitemid 350299405)
65. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561-564
66. MechoulamR,Ben-Shabat S,Hanus L, Ligumsky M, KaminskiNE, SchatzAR, Gopher A, Almog S, Martin BR, Compton DR1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50:83-90
67. Moreira FA, Grieb M, Lutz B2009) Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab 23:133-144
68. Munro S, Thomas KL, Abu-Shaar M1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65 (Pubitemid 23305569)
69. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschop MH2008) Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977-2991
70. O'Hare JD, Zielinski E, Cheng B, Scherer T, Buettner C2011) Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 60:1055-1062
71. Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, Mackie K, Palkovits M, Kunos G2005a) Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide. Neuroendocrinology 81:273-282 (Pubitemid 41397036)
72. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G2005b) Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. JClin Invest 115:1298-1305 (Pubitemid 40629049)
73. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Batkai S, Marsicano G, Lutz B, Buettner C, Kunos G2008) Hepatic CB1 receptor is required for development of dietinduced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-3169
74. Pacher P, Batkai S, Kunos G2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389-462 (Pubitemid 44394908)
75. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100 (Pubitemid 43228239)
76. Pertwee RG2005) Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168:1-51
77. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos G, Mackie K, Mechoulam R, Ross RA2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62:588-631
78. Perwitz N, Fasshauer M, Klein J2006) Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 38:356-358 (Pubitemid 43864960)
79. Piomelli D2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4:873-884 (Pubitemid 37351427)
80. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775 (Pubitemid 43244304)
81. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG1991) Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695-700
82. Proietto J, Rissanen A, Harp JB, Erondu N, Yu Q, Suryawanshi S, Jones ME, Johnson-Levonas AO, Heymsfield SB, Kaufman KD, Amatruda JM2010) A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J ObesLond) 34:1243-1254
83. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ, Fekete C, Latorre R, Nanni C, Bucci M, Clemens LE, Heldmaier G, Watanabe M, Leste-Lassere T, Maitre M, Tedesco L, Fanelli F, Reuss S, Klaus S, Srivastava RK, Monory K, Valerio A, Grandis A, De Giorgio R, Pasquali R, Nisoli E, Cota D, Lutz B, Marsicano G, Pagotto U2010) CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 11:273-285
84. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353 (Pubitemid 36120150)
85. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648 (Pubitemid 38491158)
86. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244 (Pubitemid 24268029)
87. Robson P2005) Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 168:719-756
88. Russell JC, Kelly SE, Diane A, Wang Y, Mangat R, Novak S, Vine DF, Proctor SD2010) Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome. Am J Physiol Gastrointest Liver Physiol 299:G507-G516
89. Sallan SE, Cronin C, Zelen M, Zinberg NE1980) Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 302:135-138 (Pubitemid 10211127)
90. Scheen AJ, Finer N, Hollander P, Jensen MD, van Gaal LF2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672 (Pubitemid 46048528)
91. Siler JF, Sheep WL, Bates LB, Clark GF, Cook GW, Smith WH1933) Marihuana smoking in Panama. Mil Surg 73:269-280
92. Simiand J, Keane M, Keane PE, Soubrie P1998) SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol 9:179-181 (Pubitemid 28186515)
93. Soria-Gomez E, Matias I, Rueda-Orozco PE, Cisneros M, Petrosino S, Navarro L, Di Marzo V, Prospero-Garcia O2007) Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151:1109-1116 (Pubitemid 47195529)
94. Stock MJ1997) Sibutramine: a review of the pharmacology of a novel anti- obesity agent. Int J Obes Relat Metab Disord 21(Suppl 1):S25-S29 (Pubitemid 27160696)
95. Storr MA, Sharkey KA2007) The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 7:575-582 (Pubitemid 350177551)
96. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, Osei-Hyiaman D, Ohnuma S, Ambudkar SV, Pickel J, Makriyannis A, Kunos G2010) Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk inmouse models of obesity. JClin Invest 120:2953-2966
97. Tart CT1970) Marijuana intoxication common experiences. Nature 226:701-704
98. Tedesco L, Valerio A, Cervino C, Cardile A, Pagano C, Vettor R, Pasquali R, Carruba MO, Marsicano G, Lutz B, Pagotto U, Nisoli E2008) Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57:2028-2036
99. Tedesco L,Valerio A, DossenaM, Cardile A, RagniM, Pagano C, Pagotto U, CarrubaMO, Vettor R, Nisoli E2010) Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 59:2826-2836
100. Thakur GA, Tichkule R, Bajaj S, Makriyannis A2009) Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 19:1647-1673
101. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG2006) The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84:353-359 (Pubitemid 44137303)
102. Topol EJ, Bousser MG, Fox KA, Creager MA, Després JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL2010) Rimonabant for prevention of cardiovascular eventsCRESCENDO): a randomised, multicentre, placebocontrolled trial. Lancet 376:517-523
103. Tucci SA, Rogers EK, Korbonits M, Kirkham TC2004) The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 143:520-523 (Pubitemid 39524268)
104. van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Roossner S2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397 (Pubitemid 40523733)
105. Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12:913-919 (Pubitemid 27420571)
106. Wadden TA, Fujioka K, Toubro S, Gantz I, Erondu NE, Chen M, Suryawanshi S, Carofano W, Johnson-Levonas AO, Shapiro DR, Kaufman KD, Heymsfield SB, Amatruda JM2010) A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet. ObesitySilver Spring) 18:2301-2310
107. Wallerius S, Rosmond R, Ljung T, Holm G, Bjorntorp P2003) Rise in morning saliva cortisol is associated with abdominal obesity in men: a preliminary report. J Endocrinol Invest 26:616-619 (Pubitemid 37270690)
108. Ware MA, St Arnaud-Trempe E2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494-503
109. Watanabe S, Doshi M, Hamazaki T2003) n-3 Polyunsaturated fatty acidPUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids 69:51-59 (Pubitemid 37421501)
110. Williams CM, Kirkham TC1999) Anandamide induces overeating: mediation by central cannabinoidCB1) receptors. PsychopharmacologyBerl) 143:315-317 (Pubitemid 29204987)
111. Williams CM, Kirkham TC2002) Observational analysis of feeding induced by Delta9-THC and anandamide. Physiol Behav 76:241-250 (Pubitemid 34607232)
112. Wilson RI, Nicoll RA2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410:588-592 (Pubitemid 32267203)
113. Wittmann G, Deli L, Kallo I, Hrabovszky E, Watanabe M, Liposits Z, Fekete C2007) Distribution of type 1 cannabinoid receptorCB1)-immunoreactive axons in the mouse hypothalamus. J Comp Neurol 503:270-279 (Pubitemid 47091706)
114. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI1999) Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785 (Pubitemid 29234695)